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Abstract
Background: Data on Human PapillomaVirus (HPV) infection are scarce in Morocco. The objective of the study
was to determine the prevalence of HPV and cervical cytology abnormalities in women from the Souss area,
Morocco.
Methods: Two hundred and thirty two women who attended the Hassan II hospital (Agadir, Morocco) were
recruited in this study. Socio-economic data, sexual activity, reproductive life, history of Pap smear, smoking
and HIV status were recorded. Cervical samples were taken using an Ayre spatula. Cytology was reported
using the Bethesda system. HPVs were first detected by MY09/11 consensus PCR and then genotyped with
INNO-LiPA® assay. Data were analyzed using the logistic regression model.
Results: The median age of women was 42 years (18–76 years). HIV prevalence was 36.2 %. Any HPV type
prevalence was 23.7 % in the study population, lower in HIV-negative women (13.3 %) than in HIV-positive
women (39.3 %). HPV16 was the most prevalent type (6.5 %), followed by HPV53 and HPV74 (3.4 % each).
Most women had normal cervical smears (82 %), the remaining were diagnosed with LGSIL (13 %) and HGSIL
(5 %). HPV was detected in 17.4 % of normal smears, 43.4 % of LGSIL and 75 % of HGSIL. HIV status was the
most powerful predictor of high risk (hr) and probable hr (phr) HPV infection (odds ratio 4.16, 95 % confidence interval
1.87–9.24, p = 0.0005) followed by abnormal cytology (OR 3.98, 95 % CI 1.39–11.40, p = 0.01), independently of
socio-demographic and behavioral risk factors.
Conclusions: In a Moroccan hospital based-population of the Souss area, HPV infections are frequently
detected. In addition, high prevalence of hr and phrHPVs and precancerous lesions among HIV-positive
women is likely associated with an increased risk of cervical cancer. This highlights the need for HPV and
cervical cancer prevention campaigns in Morocco.
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Background
Human papillomavirus (HPV) infection is the most
common sexually transmitted infection (STI) world-
wide and the necessary causative agent of precancer-
ous and cancerous lesions of the cervix. The role of
high risk HPV (hrHPV) in the development of virtu-
ally all cervical cancers (CC) has been well established
for more than 20 years [1–3]. CC is the second most
common cancer in Moroccan women, after breast
cancer. Current estimates indicate that the age-
standardized incidence of CC among women in
Morocco is 14.3 new cases per 100 000 women/year
corresponding to 2258 new cases /year, and the death
rate due to this disease is 7 per 100 000 correspond-
ing to 1076 cases/year [4].
To date, more than 200 HPV genotypes have been
identified. About 40 of them infect the genital tract, of
which 12 were classified as carcinogenic, one as “prob-
ably carcinogenic” and 12 as “possibly carcinogenic” to
humans [5]. HPV types 16 and 18 are responsible for
about 70 % of CC worldwide [6] and 60–70 % of high
grade lesions, depending on the geographical area [7].
However, HPV infection of the uterine cervix does not
always induce cellular abnormalities [8], indicating that
other factors play a role in the development of cervical
neoplasia. Human immunodeficiency virus (HIV) in-
fection, another STI with extensive public health im-
pact [9], shares many common behavioural risk
factors with HPV infection. HPV and HIV coinfection
increases the risk of neoplasia of the lower genital
tract [10]. Women with HIV infection commonly har-
bor a broader range of HPV genotypes, often with
multiple concurrent HPV infections, compared to
HIV-negative women [11, 12]. HIV influences the nat-
ural history of HPV by increasing virulence and the
likelihood of persistent infection, and also by hasten-
ing the time-course of HPV disease [13, 14].
In late 2013, it was estimated that there were 31 000
persons living with HIV in Morocco, with 50 % of the
cases having been registered between 2006–2013. The
Souss-Massa-Draa region of Morocco is one of the 5
areas with a high HIV burden accounting for 70 % of
notified cases [15]. In the Souss area, women who attend
public health-care clinics are most of the time not
screened and not treated for HPV-associated lesions.
Moreover, there is no epidemiological data available on
HPV infection in this region and, as such, the prevalence
of HPV infection remains unknown. Therefore, in the
present study, we evaluated the prevalence and distri-
bution of HPV genotypes, as well as cervical cytology
results, in a hospital based-population of women from
the Souss area according to demographic and lifestyle
factors and HIV status which may influence HPV
infection.
Patients and methods
Study population and sample collection
Data on cytology and HPV detection were obtained from
232 women 18 years and older who attended the Hassan
II Hospital of Agadir between June 2014 and February
2015. Patients consulted physicians for gynecological
care or for different clinical symptoms such as vaginal
discharge, vaginal bleeding, vulva itching, lower abdom-
inal and pelvic pain, infertility, menorrhagia, or other
symptoms suggestive of gynecological disorders. Women
who were virgin, pregnant or had a history of hysterec-
tomy were excluded from the study. More than 80 % of
the study population have been diagnosed with or with-
out HIV infection in a free and anonymous screening
centre (CIDAG) and HIV status was noted in medical
records.
Women received counselling regarding HPV infection
and cervical cancer screening. They underwent a pelvic
examination and cervical samples were obtained using
an extended tip “Ayre” spatula. After the conventional
cervical smear was spread onto a glass slide, the tip of
the spatula was broken off and placed in a container
containing 3 mL of universal transport medium speci-
men (UTM™) and stored at -20 °C until HPV testing.
Furthermore, interviews were conducted to record epi-
demiological data concerning socio-economic data (level
of educational, employment), sexual activity (age at first
intercourse, number of sexual partners, contraceptive
use and duration), reproductive life (age at first preg-
nancy, number of births and miscarriages, menopause),
past history of Pap smear tests, gynecological lesions
and smoking.
Informed consent was obtained prior to enrollment of
participants. The study was approved by the institutional
board of the Hassan II Hospital of Agadir and conducted
in accordance with good clinical practices to benefit the
patient.
Cytology data
The smears were processed for Papanicolaou staining
and analyzed according to the Bethesda classification as
Negative for Intraepithelial Lesion or Malignancy (NILM)
or epithelial cell abnormalities, LGSIL (Low Grade
Squamous Intraepithelial Lesion) and HGSIL (High
Grade Squamous Intraepithelial Lesion).
DNA extraction from cervical samples
DNA extraction from cervical smears was performed
using QIAamp DNA Mini Kit (Qiagen, Courtaboeuf,
France). Aliquots of 3 mL of samples were centrifugated
at 4000 rpm for 10 min, the supernatant was removed
and the pellet was resuspended in 400 μL TE buffer
(10 mM Tris–HCl, 1 mM EDTA, pH8). Then, 400 μL of
AL buffer (Qiagen) and 40 μL proteinase K (Qiagen)
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were added and the mix was digested overnight at 56 °C.
All lysates were processed according to the manufac-
turer’s instructions; DNA was eluted in 80 μL of elution
buffer and stored at -20 °C until use.
The quality of extracted DNA was controlled by
PCR amplification of the β-globin gene using the
primers PC04 (5′-CAA-CTT-CAT-CCA-CGT-TCA-CC-3′)
and GH20 (5′-GAA-GAG-CCA-AGG-ACA-GGT-AC-3′),
which gives a fragment of 265 bp.
Human Papillomavirus DNA detection and genotyping
HPV DNA was detected by a standard polymerase chain
reaction (PCR) protocol with consensus primer pair
MY09/MY11 (5′-CGT-CCM-ARR-GGA-WAC-TGA-TC-
3′ and 5′-GCM-CAG-GGW-CAT-AAY-AAT-GG-3′),
allowing the production of 450-bp fragments in the
HPV L1 open reading frame and the detection of more
than 40 low- and high-risk genital HPV types [16].
Identification of HPV genotype(s) in samples positive
Table 1 Sociodemographic, behavioral, and clinical characteristics







Primary school 38 (16.4)















Age at first pregnancy (years)
≤ 18 97 (41.8)
> 18 135 (58.2)















Yes (alone or in combination) 155 (66.8)
Intra-uterine device use
No 221 (95.2)
Yes (alone or in combination) 11 (4.8)
Table 1 Sociodemographic, behavioral, and clinical characteristics




Yes (alone or in combination) 40 (17.2)
Duration of oral contraceptive use (years)
< 5 114 (49.1)

















Abbreviations: HIV Human Immunodeficiency Virus, NILM Negative for
Intraepithelial Lesion or Malignancy, LGSIL Low-Grade Squamous Intraepithelial
Lesion, HGSIL High-Grade Squamous Intraepithelial Lesion
aPast history of gynecological lesions includes 3 anal warts, 3 vulvar
condylomas, 7 uterine polyps, 2 myomas, 3 fibromas and 12 ovarian cysts
bPerformed at entrance in the study
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for HPV DNA by MY09/11 PCR was done using the
INNO-LiPA HPV Genotyping Extra® (Fujirebio,
Courtaboeuf, France).
HPV genotyping was centrally performed at the
Department of Cellular and Molecular Biology at the
University Hospital of Besançon (France) according to
the manufacturer’s instructions. The genotyping test al-
lows the detection of 28 HPV genotypes: 18 high risk
(hr) HPV and probable hr (phr) types (HPV-16, 18, 26,
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and
82), 7 low-risk (lr) (HPV-6, 11, 40, 43, 44, 54 and 70)
and 3 HPV types not classified (HPV-69, 71 and 74).
HPV amplimers which did not hybridize to any specific
probe were considered as uncharacterized (HPVX) [17].
Statistical analysis
Quantitative and qualitative variables were described as
number and percentages. The distribution of HPV
genotypes was summarized using frequency distribution
and stratified by cytology results (NILM, LGSIL, and
HGSIL). Univariate and multivariate logistic regression
models were used to identify risk factors associated suc-
cessively with HPV infection (any HPV and/or hr and
phrHPV) and abnormal cytology. Odds ratios (ORs) and
95 % confidence intervals (CI) were used to quantify the
association between risk factors and positivity for any
HPV and/or hr and phrHPV genotypes or abnormal
cytology. A p-value <0.05 was considered statistically sig-
nificant. Statistical analyses were performed using SAS




Among the study population, 84/232 (36.2 %) women
were diagnosed HIV-positive and 105/232 (45.3 %) HIV-
negative. HIV status was unknown for 43/232 (18.5 %)
women. Table 1 describes the sociodemographic, behav-
ioral and clinical variables. Median age was 42 years
(range 18-76). The majority of women were illiterate
(66.8 %) and unemployed (84.1 %). More than half were
married (56 %), had their first intercourse at age less
than 20 (56.8 %), had their first pregnancy after 18 years
of age (58.2 %). About 41 % of women had two or three
live births, and 36 % reported one miscarriage or more.
The majority (66.4 %) reported that they had only one
lifetime sexual partner. A history of contraceptive use
was noted in three quarters of women (75.4 %) and 51 %
of women said they took oral contraception over a
period of more than 5 years. According to their answers,
10.3 % of women were smokers, 13 % had past history of
gynecological lesions including anal warts, vulvar con-
dylomas, ovarian cysts, uterine polyps, myomas and fi-
bromas and 18 % were postmenopausal. With regard to
the history of cervical cancer screening, 81.5 % of the
women had never had a Pap smear.
As regards the results of the Pap smears, 190 (81.9 %,
95 % CI [76.9 – 86.9]) were NILM, 30 (12.9 %, 95 % CI
[8.6 – 17.2]) were LGSIL and 12 (5.2 %, 95 % CI
[2.3 – 8.1]) were HGSIL. In this series, no cervical
cancer was detected.
HPV detection and genotyping
HPV DNA was detected in 23.7 % (55/232) of the cases
but 3 samples (1.3 %) could not be genotyped because
they did not match any of the specific probes of the
assay (HPVX); thus specific HPV genotypes were available
Table 2 Distribution of specific Human Papillomavirus (HPV)
genotypes in all infections (single or multiple) tested in 55
Moroccan women from the Souss area, Morocco
HPV genotypes Total n (%) NILM n (%) LGSIL n (%) HGSIL n (%)
hrHPV
16 15 (6.5) 4 (2.1) 7 (23.3) 4 (33.3)
18 7 (3.0) 2 (1.1) 2 (6.7) 3 (25.0)
31 6 (2.6) 4 (2.1) 2 (6.7) -
33 6 (2.6) 1 (0.5) 4 (13.3) 1 (8.3)
35 2 (0.9) 2 (1.1) - -
39 4 (1.7) 2 (1.1) 2 (6.7) -
45 2 (0.9) 2 (1.1) - -
51 5 (2.2) 5 (2.6) - -
52 7 (3.0) 5 (2.6) 2 (6.7) -
56 6 (2.6) 4 (2.1) 1 (3.3) 1 (8.3)
58 5 (2.2) 4 (2.1) - 1 (8.3)
68 1 (0.4) 1 (0.5) - -
82 3 (1.3) 2 (1.1) 1 (3.3) -
phr HPV
26 3 (1.3) 2 (1.1) - 1 (8.3)
53 8 (3.4) 5 (2.6) 3 (10.0) -
66 5 (2.2) 4 (2.1) 1 (3.3) -
lrHPV
6 5 (2.2) 3 (1.6) 2 (6.7) -
11 1 (0.4) - 1 (3.3) -
44 3 (1.3) 3 (1.6) - -
54 7 (3.0) 7 (3.7) - -
70 4 (1.7) 2 (1.1) 2 (6.7) -
Additional HPV
69/71 5 (2.2) 2 (1.1) 3 (10.0) -
74 8 (3.4) 7 (3.7) 1 (3.3) -
HPVX 9 (3.9) 8 (4.2) - 1 (8.3)
NILM Negative for Intraepithelial Lesion or Malignancy, LGSIL Low Grade
Squamous Intraepithelial Lesion, HGSIL High Grade Squamous
Intraepithelial Lesion
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for 52 cases. Eighteen women (34.6 %) were infected by a
single HPV genotype and 34 (65.4 %) by multiple HPV ge-
notypes. Among women with multiple genotypes, there
were 15 women with dual infection (44.1 %), 9 women
with triple infection (26.5 %), 4 women with 4 genotypes
(11.7 %) and 6 women with 5 or more genotypes (17.6 %).
Multiple infections were only half as frequent in HGSIL
(33.3 %, 3/9) as in LGSIL (69.2 %, 9/13) and NILM smears
(66.6 %, 22/33).
The distribution of HPV genotypes tested in this study
is shown in Table 2. HPV16 was the most prevalent
genotype among the study population with 4 mono-
infected women and 11 women with mixed infections
giving a total prevalence of 6.5 % (15/232). HPV53 and
HPV74 were the second most frequent genotypes in the
overall population (3.4 %, 8/232 each).
After stratifying by Pap cytology, HPV was found in
17.4 % (33/190) of women with NILM smear, in 43.3 %
(13/30) of LGSIL and in 75 % (9/12) of HGSIL. Twenty
two specific genotypes were detected in NILM smears,
15 in LGSIL and only 6 in HGSIL namely HPV16, 18,
26, 33, 56 and 58. The grade of cytological abnormalities
was highly associated with hr and phrHPV genotypes
(p = 0.001 for LGSIL and p < 0.0001 for HGSIL)
(Table 3). HPV16 was detected in 2.1 % (4/190) of
NILM, 23.3 % (7/30) of LGSIL and 33.3 % (4/12) of
HGSIL. HPV18 was the second most prevalent HPV
genotype in HGSIL (25 %, 3/12) (Table 2).
After excluding women whose HIV status was unknown,
the prevalence of HPV infection was 39.3 % (33/84,
95 % CI 28.8-49.7) in HIV infected women and
13.3 % (14/105, 95 % CI 6.8-19.8) in HIV-negative
women. Type-specific HPV distribution in the series
of HIV-positive women is shown in Fig. 1; a total of
23 individual HPV types were detected at a frequency
of more than 3.0 % in this population. The prevalence
of multiple HPV types was higher in HIV-positive
women (75.7 % (25/33), 95 % CI 66.5-84.8) compared to
HIV-negative women (57.1 % (8/14), 95 % CI 47.6 -66.5).
Among the HIV population, HPV DNA was found in
32.2 % (20/62) of NILM smears, 42.8 % (6/14) of LGSIL
and 87.5 % (7/8) of HGSIL.
Table 3 Association between infection by any HPV and by hr and phrHPV types and cytology results among Moroccan women
from the Souss area, Morocco
Cytology n (%) HPV+ n (%) OR [95 % CI] p-value hr and phra n (%) OR [95 % CI] p-value
NILM 190 (81.9) 33 (17.4) 1.00 27 (14.2) 1.00
LGSIL 30 (12.9) 13 (43.3) 4.25 [1.76–10.26] 0.001 12 (40.0) 4.02 [1.74–9.28] 0.001
HGSIL 12 (5.2) 9 (75.0) 13.97 [3.24–60.26] <0.001 9 (75.0) 18.10 [4.60–71.16] <.0001
ahr and phrHPV types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 66, 68 and 82. NILM, Negative for Intraepithelial Lesion or Malignancy; LGSIL, Low Grade
Squamous Intraepithelial Lesion; HGSIL, High Grade Squamous Intraepithelial Lesion
Fig. 1 Distribution of HPV genotypes among the 33 HIV+/HPV+ Moroccan women from the Souss area, Morocco. The prevalence of HPV
genotypes was calculated by dividing the number of women harboring specific HPV genotype as a single infection (black bars) or multiple
infections (grey bars) by the number of HIV+/HPV+ women
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Table 4 Univariate model for identification of factors associated with any HPV, hr and phrHPV genotypes and the presence of
abnormal Pap smear
Characteristic HPV+ hr and phrHPVa Abnormal Pap**
n (%) OR (95 % CI) p-value n (%) OR (95 % CI) p-value n (%) OR (95 % CI) p-value
Age (years)
≥ 45 18 (21.7) 1.00 17 (20.5) 1.00 19 (22.9) 1.00
<45 37 (24.8) 1.19 [0.63–2.26] 0.59 31 (20.8) 1.02 [0.53–1.98] 0.95 23 (15.4) 0.43 [0.22–0.85] 0.01
Educational level
Secondary and high school 9 (23.1) 1.00 7 (17.9) 1.00 2 (5.1) 1.00
Primary school 6 (15.8) 0.60 [0.19–1.91] 0.39 4 (10.5) 0.52 [0.14–1.95] 0.33 7 (18.4) 8.35 [0.97–71.65] 0.05
Illiterate 40 (25.8) 1.12 [0.49–2.57] 0.79 37 (23.9) 1.39 [0.57–3.41] 0.47 33 (21.3) 10.00 [1.32–75.68] 0.02
Employment
Yes 8 (21.6) 1.00 8 (21.6) 1.00 1 (2.7) 1.00
No 47 (24.1) 1.15 [0.49–2.69] 0.75 40 (20.5) 0.94 [0.40–2.20] 0.88 41 (21) 9.58 [1.27–72.00] 0.03
Marital status
Married 26 (20.0) 1.00 21 (16.1) 1.00 18 (13.8) 1.00
Single + divorced + widowed 29 (28.4) 1.59 [0.87–2.92] 0.14 27 (26.5) 1.87 [0.98–3.55] 0.05 24 (23.5) 1.51 [0.77–2.96] 0.22
HIV status
Negative 14 (13.3) 1.00 13 (12.4) 1.00 12 (11.4) 1.00
Positive 33 (39.3) 4.21 [2.06–8.58] <0.0001 29 (34.5) 3.73 [1.79–7.78] 0.0004 22 (26.2) 2.75 [1.27–5.96] 0.01
Age at first intercourse (years)
≥20 23 (23.0) 1.00 20 (20) 1.00 14 (14) 1.00
17–19 14 (21.2) 1.15 [0.50–2.64] 0.73 12 (18.2) 1.65 [0.72–3.82] 0.24 12 (18.2) 1.60 [0.63–4.09] 0.32
≤16 18 (27.3) 1.61 [0.73–3.56] 0.24 16 (24.2) 1.15 [0.48–2.77] 0.76 16 (24.2) 2.31 [0.94–5.66] 0.06
Age at first pregnancy (years)
> 18 28 (20.7) 1.00 24 (17.7) 1.00 22 (16.3) 1.00
≤ 18 32 (32.9) 1.47 [0.8–2.71] 0.21 24 (24.7) 1.52 [0.80–2.98] 0.20 20 (20.6) 1.19 [0.60–2.32] 0.62
Number of live births
0–1 22 (26.5) 1.00 18 (21.7) 1.00 14 (63.6) 1.00
2–3 23 (23.9) 0.87 [0.44–1.72] 0.69 21 (21.9) 1.01 [0.50–2.06] 0.97 21 (21.9) 1.38 [0.65–2.92] 0.40
≥4 10 (18.8) 0.65 [0.28–0.50] 0.30 9 (17) 0.74 [0.30–1.79] 0.50 7 (13.2) 0.75 [0.28–2.00] 0.56
Number of miscarriage
0 33 (22.1) 1.00 27 (18.1) 1.00 19 (12.7) 1.00
≥1 22 (26.5) 1.27 [0.68–2.36] 0.45 21 (25.3) 1.53 [0.80–2.92] 0.20 23 (27.7) 2.06 [1.05–4.06] 0.03
Number of sexual partners
Single 33 (21.4) 1.00 26 (16.8) 1.00 27 (17.5) 1.00
multiple 22 (28.2) 1.44 [0.77–2.69] 0.25 21 (26.9) 1.93 [1.01–3.70] 0.04 15 (19.2) 0.86 [0.42–1.77] 0.68
History of contraception use
No 11 (19.3) 1.00 10 (17.5) 1.00 9 (15.8) 1.00
Yes 44 (25.1) 0.40 [0.67–2.95] 0.37 38 (21.7) 1.30 [0.60–2.82] 0.50 33 (18.8) 1.05 [0.48–2.30] 0.89
Oral contraceptive use
No 16 (20.7) 1.00 14 (18.2) 1.00 13 (16.8) 1.00
Yes (alone or in combination) 39 (25.1) 1.28 [0.66–2.48] 0.46 34 (21.9) 1.26 [0.63–2.53] 0.51 29 (18.7) 0.87 [0.43–1.75] 0.70
Condom use
No 44 (22.9) 1.00 38 (19.8) 1.00 0.46 35 (18.2) 1.00
Yes (alone or in combination) 11 (27.5) 1.28 [0.59–2.76] 0.54 10 (25) 1.35 [0.61–3.00] 7 (17.5) 1.16 [0.49–2.74] 0.73
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Risk factors
The association between any HPV, hr and phrHPV,
abnormal smear and sociodemographic characteristics as
well as sexual behavior was also investigated in the
population. By univariate analysis, hr and phrHPV ge-
notypes were associated with number of sexual part-
ners (p = 0.04), smoking exposure (p = 0.03) and HIV
infection (p = 0.0004) (Table 4). By multivariate ana-
lysis, HIV positivity was associated with a significantly
increased risk of hr and phrHPV infection (OR 4.16,
95 % CI 1.87-9.24, p = 0.0005) after adjustment for
educational level, marital status, age at first preg-
nancy, number of miscarriages, number of sexual
partners and smoking exposure (Table 5).
In a second univariate analysis, abnormal Pap smears
were associated with unemployment (OR 9.58, 95 % CI
1.27-72.00, p = 0.03), number of miscarriages (OR 2.06,
95 % CI 1.05-4.06, p = 0.03) and HIV infection (OR 2.75,
95 % CI 1.27-5.96, p = 0.01) (Table 4). By multivariate
analysis, HIV positivity and number of miscarriages were
associated with a significant increase in the risk of
abnormal Pap smears (OR 3.98, 95 % CI 1.39-11.40,
p = 0.01; OR 2.84, 95 % CI 1.14-7.12, p = 0.02 respect-
ively) after adjustment for age, educational level, em-
ployment, age at first intercourse, menopause and
number of Pap smears (Table 6).
Discussion
In Morocco, cervical cancer (CC) is the second cause of
cancer deaths in women after breast cancer, and repre-
sents a major public health problem. Here, we observed
that more than 80 % of women had never been screened
for CC, and the prevalence of HPV infection was high
(23.7 %), with differences according to HIV status. In-
deed, the rate of HPV was 13.3 % in HIV-negative
Table 4 Univariate model for identification of factors associated with any HPV, hr and phrHPV genotypes and the presence of
abnormal Pap smear (Continued)
Smoking exposure
No 46 (22.1) 1.00 39 (18.7) 1.00 36 (17.3) 1.00
Yes 9 (37.5) 2.11 [0.87–5.14] 0.1 9 (37.5) 2.60 [1.06–6.37] 0.03 6 (25) 0.89 [0.29–2.77] 0.84
History of gynecological lesions
No 49 (24.2) 1.00 43 (21.3) 1.00 36 (17.8) 1.00
Yes 6 (20.0) 1.28 [0.50–3.31] 0.61 5 (16.7) 1.35 [0.49–3.74] 0.56 6 (20) 1.12 [0.4–3.12] 0.82
Menopause
No 47 (24.7) 1.00 40 (21) 1.00 33 (17.3) 1.00
Yes 8 (19.0) 1.40 [0.60–3.23] 0.43 8 (19) 1.13 [0.49–2.64] 0.77 9 (21.4) 0.55 [0.25–1.20] 0.13
Number of Pap smears
never 48 (25.4) 1.00 41 (21.7) 1.00 37 (19.5) 1.00
≥1 7 (16.3) 0.57 [0.24–1.37] 0.21 7 (16.3) 0.70 [0.29–1.69] 0.43 5 (11.6) 0.54 [0.20–1.47] 0.22
ahr and phrHPV types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 66, 68 and 82. ** LGSIL, Low Grade Squamous Intraepithelial Lesion and HGSIL, High Grade
Squamous Intraepithelial Lesion
Table 5 Multivariate analysisa of the characteristics associated
with hr and phrHPV types
Characteristics OR (95 % CI) p-value
Educational level
Secondary and high school 1.00
Primary school 0.51 [0.12–2.05] 0.34
Illiterate 1.35 [0.49–3.68] 0.56
Marital status
Married 1.00
Single or divorced or widowed 1.17 [0.50–2.73] 0.72
HIV status
Negative 1.00
Positive 4.16 [1.87–9.24] 0.0005
Age at first pregnancy (years)
> 18 1.00
≤ 18 1.41 [0.66–3.03] 0.38
Number of miscarriages
0 1.00
≥1 0.96 [0.45–2.07] 0.92
Number of sexual partners
Single 1.00
Multiple 0.71 [0.30–1.70] 0.44
Smoking exposure
No 1.00
Yes 2.04 [0.65–6.42] 0.22
aThe model included all variables with a p-value ≤ 0.2 by univariate analysis
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women and 39.3 % in HIV-positive women. Three
Moroccan studies in patients attending the Hospital in
Rabat [18, 19] and Casablanca [20] reported results simi-
lar to ours. The overall prevalence of HPV was lower
(6 %) in the study by Amrani et al., but the number of
cytological intraepithelial lesions was low (2.5 % LGSIL
and 0.7 % HGSIL) [21] compared to our series (12.9 %
of LGSIL and 5.2 % of HGSIL). By contrast, the rate of
HPV was high in two geographical areas with high inci-
dence of CC (according to the Rabat and Casablanca
Cancer Registries), reaching 32 % in a series of women
living in Rabat [22] and 42.5 % in women with normal
cytology native of north-central of Morocco [23]. We
cannot exclude a bias in the latter studies that did not
report HIV status of women. As in most developing
countries, some cultural factors can be related to this
high HPV prevalence, especially misconceptions and be-
liefs that prevent people from discussing diseases of the
genital tract.
In our study, HPV16 was the most prevalent genotype
among the overall HPV-positive population, followed by
HPV53 and HPV74. This is in line with studies from
around the world, where HPV16 was identified as the
most common hrHPV [24–26]. HPV16 and HPV18 repre-
sented 3.3 % in NILM smears, 30 % in LGSIL and 58.3 %
of HGSIL (Table 2). This finding is consistent with data
published recently by the Morocco-ICO Information
Centre on HPV and Cancers [4]. Bearing in mind that
HPV16 and 18 are responsible for about 70 % of CC cases
[3, 27, 28], we suggest the need for HPV screening and
anti-HPV vaccination as a primary preventive measure
among Moroccan women.
We noted that low risk HPV types were found in 8 %
of women with NILM smears and 16.7 % of women with
LGSIL but not in women with HGSIL. This confirms
that lrHPV rarely cause CIN3 or cancer [29–31].
Interestingly, in the present study, multiple HPV infec-
tions were observed in 65.4 % of HPV-positive speci-
mens, but only in 33.3 % of HGSIL cases. Meftah el
khair et al. reported 34 % of multiple infections in CC
from Moroccan women [32]. Co-infection with multiple
HPV genotypes has been described in many molecular
epidemiologic studies [33–35] and confers an increased
risk of high-grade lesions and invasive cervical cancer
[36]. This has recently been confirmed in a study includ-
ing 5,871 sexually active women aged 18-25 years from
Costa Rica, in which Chaturvedi et al. reported that
women with multiple infections were at significantly in-
creased risk of CIN2+ and HGSIL+ as compared with
those with single infections [34]. The present findings
provide evidence that women with multiple infections
should be closely monitored to prevent progression to
CC especially in the context of co-infection with HIV.
Reported data on smoking and sexual behavior may be
biased because the women may give what is believed to
be the desired or socially acceptable answers. This would
result in the absence of association between known risk
factors with HPV infection in our population.
By contrast, a significant association was found
between HIV infection and hr and phrHPV as well as
between HIV infection and abnormal cytology. An im-
portant clinical consequence of our results is that HIV
appears to be the strongest risk factor for HPV infection,
independently of the usual socio-demographic and be-
havioural risk factors.
In the Souss area, the burden of HIV/AIDS is high. In
female sex-workers, the prevalence of HIV is above 5 %
in Agadir [15]. In recent years, HIV-infected women
were referred from the infectious diseases department of
the Hassan II Hospital in Agadir to the pathology
Table 6 Multivariate analysis*of the characteristics associated
with an abnormal cytology (Low Grade and High-Grade
Squamous Intraepithelial Lesion)
Characteristics OR [95 % CI] p-value
Age (years)
<45 1.00
≥ 45 0.30 [0.09–1.01] 0.052
Educational level
Secondary and high school 1.00
Primary school 3.77 [0.44–32.36] 0.23
Illiterate 3.18 [0.30–33.71] 0.34
Employment
No 1.00
Yes 5.86 [0.69–50.13] 0.11
HIV status
Negative 1.00
Positive 3.98 [1.39–11.40] 0.01
Age at first intercourse (years)
≥20 1.00
17–19 2.41 [0.64–9.08] 0.19
≤16 2.43 [0.69–8.60] 0.17
Number of miscarriages
0 1.00
≥1 2.84 [1.14–7.12] 0.02
Menopause
No 1.00
Yes 1.33 [0.35–5.12] 0.68
Number of Pap smears
Never 1.00
≥1 0.74 [0.20–2.66] 0.64
*The model included all variables with a p-value ≤ 0.2 by univariate analysis as
well as variables considered to be important (Pap screening)
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department of the same Hospital for CC screening at no
cost. To the best of our knowledge, there are no
previously published studies from Morocco that have in-
vestigated the prevalence of HPV genotypes in the popu-
lation of HIV-positive women, and the relationship
between HPV, HIV and cervical cytology. The prevalence
of HPV infection in HIV+ women with normal smears
(32.2 %) is quite similar to that published in the
meta-analysis of Clifford et al. reporting a 36.3 %
HPV prevalence among 3230 HIV-infected women
with no cytological abnormalities [11]. Moreover, mul-
tiple infections were found in 75.7 % of HIV-positive
women. This is in agreement with the study of
Stuardo et al. who reported 78.4 % of multiple infec-
tions in HIV-infected Spanish women [37] and con-
sistent with data from other studies showing that
HIV-infected women not only have a higher preva-
lence of HPV infection, but are also infected by a
wider variety of HPV types than HIV-negative [11, 38, 39].
This has been attributed to lower clearance of HPV
[10, 40] or continued sexual exposure to novel HPV
types allowing different viral types to settle in the cer-
vical epithelium. Multiple infections could also be due
to the reduced systemic and local immunity in HIV-
positive women [41].
This study has limitations. The limited number of
women included in the study may explain the absence of
significant relationship between HPV infection and clas-
sical risk factors such as sexual habits. Furthermore, the
study population is not representative of the general
population of the Souss area. However, this pilot study
on a hospital based-population in Agadir is groundwork
and a great opportunity to define a more complete re-
search in the future.
In summary, the high prevalence of HPV infection and
the diverse distribution of HPV genotypes among
Moroccan women from the Souss area emphasizes the
need to implement CC screening programs and HPV
vaccination for primary prevention [42].
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